Ixazomib citrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for ixazomib citrate and what is the scope of freedom to operate?
Ixazomib citrate
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ixazomib citrate has two hundred and twenty-three patent family members in forty-six countries.
One supplier is listed for this compound.
Summary for ixazomib citrate
International Patents: | 223 |
US Patents: | 9 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 37 |
Patent Applications: | 617 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ixazomib citrate |
DailyMed Link: | ixazomib citrate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ixazomib citrate
Generic Entry Date for ixazomib citrate*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ixazomib citrate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
AIDS Malignancy Consortium | Phase 2 |
Sun Yat-sen University | Phase 2 |
Takeda | Phase 2 |
Pharmacology for ixazomib citrate
Drug Class | Proteasome Inhibitor |
Mechanism of Action | Proteasome Inhibitors |
Paragraph IV (Patent) Challenges for IXAZOMIB CITRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NINLARO | Capsules | ixazomib citrate | 2.3 mg, 3 mg and 4 mg | 208462 | 1 | 2019-11-20 |
US Patents and Regulatory Information for ixazomib citrate
International Patents for ixazomib citrate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 5926319 | ⤷ Try a Trial | |
Singapore | 194349 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | ⤷ Try a Trial |
Philippines | 12015501191 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | ⤷ Try a Trial |
Taiwan | 200914460 | Proteasome inhibitors | ⤷ Try a Trial |
Peru | 20100256 | COMPUESTOS DE ESTER BORONATO Y COMPOSICIONES FARMACEUTICAS DE LOS MISMOS | ⤷ Try a Trial |
Philippines | 12015501192 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ixazomib citrate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2178888 | 275 50004-2017 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: IXAZOMIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1094 20161123 |
2178888 | 1790016-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: IXAZOMIB AND PHARMACEUTICALLY ACCEPTABLE SALTS AND ESTERS THEREOF, SUCH AS IXAZOMIB CITRATE; REG. NO/DATE: EU/1/16/1094 20161123 |
2178888 | 17C1011 | France | ⤷ Try a Trial | PRODUCT NAME: IXAZOMIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET SES ESTERS TELS QUE LE CITRATE D'IXAZOMIB; REGISTRATION NO/DATE: EU/1/16/1094 20161123 |
2178888 | 2017/016 | Ireland | ⤷ Try a Trial | PRODUCT NAME: IXAZOMIB; REGISTRATION NO/DATE: EU/1/16/1094 20161121 |
2178888 | 300871 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IXAZOMIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN EN ESTERS DAARVAN, ZOALS IXAZOMIBCITRAAT; REGISTRATION NO/DATE: EU/1/16/1094 20161123 |
2178888 | C 2017 012 | Romania | ⤷ Try a Trial | PRODUCT NAME: IXAZOMIB SI SARURI SI ESTERI AI ACESTUIA ACCEPTABILE FARMACEUTIC, CA CITRAT DE IXAZOMIB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1094; DATE OF NATIONAL AUTHORISATION: 20161121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1094; DATE OF FIRST AUTHORISATION IN EEA: 20161121 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.